<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-108904" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Methocarbamol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sibrack</surname>
            <given-names>Jeffrey</given-names>
          </name>
          <aff>Tulane University SOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hammer</surname>
            <given-names>Rachel</given-names>
          </name>
          <aff>Tulane University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeffrey Sibrack declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rachel Hammer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-108904.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Classified as a skeletal muscle relaxant, methocarbamol is a helpful&#x000a0;medication used to&#x000a0;manage&#x000a0;acute musculoskeletal pain. This&#x000a0;activity&#x000a0;focuses&#x000a0;on the pivotal indications, mechanism of action, and contraindications of methocarbamol in the treatment mosaic for acute musculoskeletal pain. With a spotlight on considerations including adverse events, efficacy evidence, drug interactions, and monitoring imperatives, healthcare professionals are empowered to tailor treatment strategies adeptly. By&#x000a0;discussing the pharmacology of methocarbamol, healthcare professionals are equipped to&#x000a0;address&#x000a0;patient needs with precision, underscoring the indispensable role of the interprofessional healthcare team in orchestrating methocarbamol therapy for pain alleviation in musculoskeletal domains.</p>
        <p>This activity&#x000a0;gives healthcare professionals&#x000a0;indispensable insights and tools for optimal patient care&#x000a0;involving methocarbamol administration. With this knowledge, healthcare professionals can&#x000a0;make informed decisions and fine-tune dosage regimens while circumventing&#x000a0;adverse reactions. This educational&#x000a0;discussion&#x000a0;employs evidence-based medicine and&#x000a0;will&#x000a0;elevate patient outcomes in conditions necessitating methocarbamol for mitigating musculoskeletal pain and associated&#x000a0;conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the indications for the use of methocarbamol in the treatment of musculoskeletal pain.</p></list-item><list-item><p>Determine&#x000a0;populations at risk for adverse effects of methocarbamol.</p></list-item><list-item><p>Assess&#x000a0;different approaches for using anti-spastic and anti-spasmodic classes of skeletal muscle relaxants.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from methocarbamol pharmacotherapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=108904&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=108904">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-108904.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Methocarbamol is classified as a centrally-acting skeletal muscle relaxant (SMR) that is United States Food and Drug Administration (FDA)-approved for&#x000a0;managing&#x000a0;acute musculoskeletal pain. Methocarbamol has been FDA-approved for muscle spasms since 1957.<xref ref-type="bibr" rid="article-108904.r1">[1]</xref>&#x000a0;The clinical efficacy of methocarbamol is established within the larger class of muscle relaxants.<xref ref-type="bibr" rid="article-108904.r2">[2]</xref>&#x000a0;Methocarbamol is an anti-spasmodic agent used to treat involuntary skeletal muscle spasms, differentiating it from anti-spastic agents like dantrolene and baclofen, which are specifically designed to address spasticity resulting from upper motor neuron disorders. Other commonly prescribed anti-spasmodic agents include carisoprodol and cyclobenzaprine. Additionally, diazepam and tizanidine have anti-spastic and anti-spasmodic properties.<xref ref-type="bibr" rid="article-108904.r3">[3]</xref>&#x000a0;These anti-spasmodic and anti-spastic medications have distinct mechanisms of action. However, this discussion will concentrate on methocarbamol for the scope of this review.</p>
        <p>Methocarbamol was discovered in the early 1950s and received regulatory approval in 1957.<xref ref-type="bibr" rid="article-108904.r1">[1]</xref>&#x000a0;In 1958, O'Doherty and Shields reported that methocarbamol effectively treats muscle spasms in patients with pyramidal spine lesions, such as herniated intervertebral discs.<xref ref-type="bibr" rid="article-108904.r4">[4]</xref>&#x000a0;Concurrent with the research of O'Doherty and Shields, Forsyth demonstrated methocarbamol's efficacy in a case series of 100 patients with orthopedic conditions, including post-operative muscle spasm acute and chronic disc herniation. In the published study, all but&#x000a0;6 patients experienced either a "moderate" or "pronounced" relief in subjective pain or spasms. No significant adverse effects were observed, and only 9 patients reported "minor" adverse effects, including dizziness and nausea.<xref ref-type="bibr" rid="article-108904.r5">[5]</xref>&#x000a0;Despite its common use today, few high-quality studies and no meta-analyses compare methocarbamol to placebo or alternative agents for muscle spasms.<xref ref-type="bibr" rid="article-108904.r6">[6]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Today, the clinical use of methocarbamol is typically confined to the adjunctive treatment of acute pain of musculoskeletal origin. According to the American College of Physicians guidelines, nonpharmacologic therapies for acute or subacute low back pain should be prioritized. If pharmacologic treatment is desired, nonsteroidal anti-inflammatory drugs and skeletal muscle relaxants like methocarbamol are also available.<xref ref-type="bibr" rid="article-108904.r7">[7]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Off-label use of methocarbamol&#x000a0;has been investigated for a range of painful disorders, including acute and chronic non-specific low-back pain, inflammatory arthritis, fibromyalgia, rib fractures, myofascial pain, abdominal muscle cramps in patients with cirrhosis and perioperative care of hip and knee replacements.<xref ref-type="bibr" rid="article-108904.r8">[8]</xref><xref ref-type="bibr" rid="article-108904.r9">[9]</xref><xref ref-type="bibr" rid="article-108904.r10">[10]</xref><xref ref-type="bibr" rid="article-108904.r11">[11]</xref><xref ref-type="bibr" rid="article-108904.r12">[12]</xref>&#x000a0;Benzodiazepines have replaced methocarbamol for tetanus treatment.<xref ref-type="bibr" rid="article-108904.r13">[13]</xref>&#x000a0;Methocarbamol is ineffective for treating contracture, rigidity, or spasticity, which is believed to originate from upper motor neuron injury. A recent case report has described the potential use of methocarbamol for tizanidine withdrawal.<xref ref-type="bibr" rid="article-108904.r14">[14]</xref></p>
      </sec>
      <sec id="article-108904.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The precise mechanism of action of methocarbamol remains unknown. In theory, involuntary muscle spasms may result from a protective reflex preventing movement that would otherwise cause injury. However, in some cases, muscle spasms themselves may become painful and debilitating. This phenomenon, known as the "pain-spasm-pain cycle," has not been confirmed in rigorous clinical and electrophysiologic studies.<xref ref-type="bibr" rid="article-108904.r9">[9]</xref>&#x000a0;Along with other muscle relaxants, the discovery and development of methocarbamol were based on animal studies that observed decreased muscle tone without concurrent depression of motor activity.<xref ref-type="bibr" rid="article-108904.r15">[15]</xref>&#x000a0;Theoretically, the relief skeletal muscle relaxants (SMR) provide results from global central nervous system depression. The other proposed mechanism is anticholinergic inhibition of the midbrain reticular activating system, which results in depressed polysynaptic reflexes and reduced muscle tone. This is also characterized as an indirect inhibition of the interneuronal junction of the spinal cord. Methocarbamol does not directly affect the skeletal muscle contractility, motor nerve fiber, or motor end plate.<xref ref-type="bibr" rid="article-108904.r4">[4]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> The onset of action of oral methocarbamol is 30 minutes. Methocarbamol is well absorbed&#x000a0;in the gastrointestinal tract and attains peak plasma concentrations at&#x000a0;2 hours.<xref ref-type="bibr" rid="article-108904.r16">[16]</xref></p>
        <p><bold>Distribution:</bold> Methocarbamol demonstrates moderate binding to plasma proteins, typically ranging from 46% to 50%.</p>
        <p><bold>Metabolism:</bold> Methocarbamol undergoes metabolic processes predominantly via dealkylation and hydroxylation pathways, potentially followed by conjugation.</p>
        <p><bold>Elimination:</bold> In healthy volunteers, methocarbamol exhibits plasma clearance rates ranging from 0.20 to 0.80 L/h/kg and an average plasma elimination half-life spanning 1 to 2 hours. Methocarbamol is&#x000a0;primarily excreted as an inactive metabolite in the urine. Methocarbamol is typically dosed every&#x000a0;6 hours based on observed clinical pharmacokinetics. One study of methocarbamol in hemodialysis patients demonstrated no alteration in elimination time compared to control patients; however, renal clearance was reduced.<xref ref-type="bibr" rid="article-108904.r17">[17]</xref>&#x000a0;Clearance is also reduced in patients with cirrhosis; however, no specific dose adjustment is suggested. In one study, a dosage of 500 mg given twice daily was well tolerated by patients with cirrhosis.<xref ref-type="bibr" rid="article-108904.r12">[12]</xref></p>
      </sec>
      <sec id="article-108904.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Methocarbamol is commonly administered via the oral route. Methocarbamol is commercially available in 500 mg and 750 mg tablets. Intravenous (IV) and intramuscular (IM) formulations may also be used commonly in the post-operative setting.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The daily recommended dosing ranges from&#x000a0;4 to 6 grams orally in divided doses every&#x000a0;6 hours. The maximum recommended dosage is 6 grams daily, and up to 8 grams daily have been utilized. However, lower doses are&#x000a0;more common in clinical practice. For example, in a retrospective cohort study, the typical dose of methocarbamol for a hospitalized patient was 500 mg orally every&#x000a0;8 hours.<xref ref-type="bibr" rid="article-108904.r10">[10]</xref>&#x000a0;Intravenous (IV) and intramuscular (IM) formulations may also be used commonly in the post-operative setting. One gram can be injected every&#x000a0;8 hours by IM or IV route. The dosage should not exceed&#x000a0;3 grams daily, and methocarbamol should not be used for more than&#x000a0;3 consecutive days.<xref ref-type="bibr" rid="article-108904.r18">[18]</xref><xref ref-type="bibr" rid="article-108904.r19">[19]</xref></p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Renal impairment:&#x000a0;</bold>All major metabolites of methocarbamol are excreted in the urine. Similarly, small amounts of unchanged methocarbamol are excreted in the urine. The intravenous formulation of methocarbamol is contraindicated in renal impairment due to the presence of polyethylene glycol excipient. The oral methocarbamol should be cautiously used for patients with mild to moderate renal impairment. Healthcare providers should be cautious when giving methocarbamol to patients who are undergoing dialysis.<xref ref-type="bibr" rid="article-108904.r17">[17]</xref></p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Methocarbamol is metabolized via liver dealkylation, hydroxylation, and conjugation. However, manufacturer labels do not provide dose recommendations.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Methocarbamol&#x000a0;is considered a pregnancy category C medicine. Case reports have documented fetal and congenital abnormalities in pregnant women exposed to methocarbamol. As a result, this medication should not be used by women who are pregnant or may become pregnant, especially in the early stages of pregnancy, unless the potential benefits significantly outweigh the risks.<xref ref-type="bibr" rid="article-108904.r20">[20]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;No studies have been conducted to evaluate methocarbamol use in breastfeeding women. The manufacturer recommends using caution when administering methocarbamol to a nursing woman. Methocarbamol is known to cross the placental barrier and is excreted in breast milk,&#x000a0;according to&#x000a0;animal studies. Therefore, it is not recommended for use in women who may become pregnant or who are breastfeeding.</p>
        <p><bold>Pediatric patients:</bold> The efficacy and safety of methocarbamol in patients younger than 16 have not been established.</p>
        <p><bold>Older patients</bold>: SMRs, including methocarbamol, are included in the Beers Criteria as medications that should be avoided in adults older than 65. They have been associated with a small but statistically significant increase in injury for older patients. This theoretical "injury" is based on retrospective case-control analyses evaluating patients who present to urgent care facilities, emergency rooms, and hospitals. The primary diagnoses of concern include falls, non-vertebral fractures, soft-tissue injuries, and other cognitive or psycho-motor disruptions. The absolute risk increase from methocarbamol calculated from the extant data is approximately 0.2%. All SMRs share anticholinergic properties that may contribute to sedation, falls, confusion, and polypharmacy in older patients, and methocarbamol is no exception.<xref ref-type="bibr" rid="article-108904.r21">[21]</xref><xref ref-type="bibr" rid="article-108904.r22">[22]</xref></p>
      </sec>
      <sec id="article-108904.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Severe adverse effects noted in the methocarbamol package insert include seizures, leukopenia, and cholestatic jaundice. According to the LiverTox resource governed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), methocarbamol has not been linked to liver or kidney injury.<xref ref-type="bibr" rid="article-108904.r1">[1]</xref>&#x000a0;According to drug monographs, there have been reports of seizures in patients with a history of epilepsy after IV administration and cases of polysubstance toxicity. The product labeling indicates that neurologic adverse drug reactions are more common, with sedation being the most prevalent, followed by dizziness and headache. Other reported neurologic adverse drug reactions include confusion, amnesia, falls, syncope, and diplopia. Gastrointestinal adverse effects include dyspepsia, nausea, emesis, metallic taste, and cholestatic jaundice. IV administration of methocarbamol has been associated with thrombophlebitis and injection site pain related to the extravasation of hypertonic solution. Methocarbamol may cause urine discoloration, but this is not clinically significant.<xref ref-type="bibr" rid="article-108904.r23">[23]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>There have been multiple studies assessing the abuse potential of methocarbamol. Animal studies have demonstrated low abuse potential when methocarbamol is compared to barbiturates and benzodiazepines.<xref ref-type="bibr" rid="article-108904.r24">[24]</xref>&#x000a0;However, multiple human studies have reported abuse potential.<xref ref-type="bibr" rid="article-108904.r25">[25]</xref><xref ref-type="bibr" rid="article-108904.r26">[26]</xref>&#x000a0;Despite abuse concerns, a recent review of German pharmacovigilance data did not indicate abuse potential for methocarbamol. However, the authors noted that under-reporting of adverse effects was a limitation of the study, so the concern for abuse should remain. Exercise caution when prescribing methocarbamol to patients who are also prescribed multiple central nervous system depressants, such as opioids and benzodiazepines, or who have known substance use disorders.<xref ref-type="bibr" rid="article-108904.r27">[27]</xref></p>
      </sec>
      <sec id="article-108904.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>According to the FDA, methocarbamol is contraindicated in patients with a history of drug hypersensitivity to methocarbamol or excipient.&#x000a0;In addition, IV-administered methocarbamol is contraindicated in renal impairment due to the presence of excipient polyethylene glycol, which is independently associated with metabolic acidosis, renal injury, and hyperosmolarity.<xref ref-type="bibr" rid="article-108904.r28">[28]</xref>&#x000a0;There have been multiple studies assessing the abuse potential of methocarbamol. Animal studies have demonstrated low abuse potential when methocarbamol is compared to benzodiazepines and barbiturates.<xref ref-type="bibr" rid="article-108904.r24">[24]</xref>&#x000a0;However, considerable human studies have reported abuse potential.<xref ref-type="bibr" rid="article-108904.r25">[25]</xref><xref ref-type="bibr" rid="article-108904.r26">[26]</xref>&#x000a0;Despite abuse concerns, a recent review of German pharmacovigilance data did not indicate abuse potential for methocarbamol; however, the authors noted that under-reporting of adverse effects was a limitation of the study, so the concern for abuse should remain. Methocarbamol should be used with caution on multiple central nervous system (CNS) depressants, including benzodiazepines, opioids, and known substance use disorders.</p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p><bold>Myasthenia gravis:</bold> Methocarbamol should not be prescribed in patients with myasthenia gravis who are taking acetylcholinesterase inhibitors. This recommendation is in the package insert and based on a case report of an exacerbation of muscle weakness and fatigue associated with methocarbamol's anticholinergic effects.<xref ref-type="bibr" rid="article-108904.r29">[29]</xref>&#x000a0;</p>
        <p><bold>Beers criteria:</bold> As stated earlier, methocarbamol is included in the Beers Criteria and should be avoided in the geriatric population due to the risk of falls, fractures, soft-tissue injuries, and other cognitive or psychomotor impairments.<xref ref-type="bibr" rid="article-108904.r21">[21]</xref></p>
        <p><bold>Drug-laboratory interference:</bold> Methocarbamol can interfere with urine screening of vanillyl mandelic acid (VMA) and 5-hydroxy indole acetic acid (5-HIAA).<xref ref-type="bibr" rid="article-108904.r30">[30]</xref></p>
      </sec>
      <sec id="article-108904.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Recommended monitoring of methocarbamol involves evaluating the clinical response and mitigating the risk of the emergence of adverse effects. There is no requirement to check blood chemistry in follow-up or therapeutic drug monitoring. Specific populations at risk for toxicity include cirrhosis, use of multiple CNS depressants, renal impairment, substance use disorders, and older patients.<xref ref-type="bibr" rid="article-108904.r22">[22]</xref></p>
      </sec>
      <sec id="article-108904.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Isolated methocarbamol overdose is rare and unlikely to be life-threatening in the absence of multiple drug exposures.<xref ref-type="bibr" rid="article-108904.r31">[31]</xref>&#x000a0;Based on limited data, toxicity symptoms may include nausea, sedation, seizures, coma, and death.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There is no antidote for methocarbamol overdose. Treatment is supportive.&#x000a0;One retrospective study utilizing National Poison Data System data aimed to characterize poisoning exposures to skeletal muscle relaxants in pediatric and adolescent populations. From 2010 to 2020, a study identified 2605 cases of single-agent exposures to carisoprodol, meprobamate, methocarbamol, or metaxalone in patients aged 6 to 19. Findings revealed that the majority of cases (75.74%) were intentional exposures, with suicide attempts accounting for over half of these incidents. Clinical effects commonly observed included drowsiness, tachycardia, vomiting, and slurred speech. Most exposures (81.04%) resulted in referral or management at healthcare facilities, with intravenous fluids and activated charcoal commonly administered interventions. The study underscores the importance of understanding skeletal muscle relaxant toxicity in adolescents to inform effective management strategies.<xref ref-type="bibr" rid="article-108904.r32">[32]</xref></p>
      </sec>
      <sec id="article-108904.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>SMRs, including methocarbamol, are commonly prescribed for non-specific musculoskeletal pain. In 2004, an estimated&#x000a0;2 million American adults took a muscle relaxant, the most common indication being low back pain.<xref ref-type="bibr" rid="article-108904.r33">[33]</xref>&#x000a0;Low back pain was among the leading causes of years lived with disability globally in 2016.<xref ref-type="bibr" rid="article-108904.r34">[34]</xref>&#x000a0;A specific nociceptive etiology of low back pain is often elusive. In such cases, symptoms result from multiple factors, including biomechanical pain generators, central and peripheral nociceptive processing, medical comorbidity, and psychosocial factors.<xref ref-type="bibr" rid="article-108904.r35">[35]</xref>&#x000a0;A biopsychosocial approach is encouraged when a specific etiology cannot be identified due to the complexity of factors contributing to low back pain. First-line recommendations are non-pharmacologic, including patient education, maintaining activity, and using heat and ice.<xref ref-type="bibr" rid="article-108904.r36">[36]</xref>&#x000a0;Pharmacologic treatments are an option for those with persistent symptoms but should be part of a multi-modal treatment plan that may include psychological and biomechanically oriented therapies.</p>
        <p>Despite more than&#x000a0;3 million methocarbamol prescriptions&#x000a0;annually in the United States, limited high-quality data is available to demonstrate clinical efficacy.<xref ref-type="bibr" rid="article-108904.r1">[1]</xref>&#x000a0;Methocarbamol is superior to placebo for acute musculoskeletal pain and similar to other muscle relaxants. However, this conclusion is based mostly on dated, small case series and small randomized clinical trials (RCT).<xref ref-type="bibr" rid="article-108904.r37">[37]</xref>&#x000a0;There is conflicting evidence regarding whether methocarbamol is superior to or provides any additional benefit compared to NSAIDs. In a randomized controlled trial conducted in 2018, Friedman et al found that adding methocarbamol to naproxen did not improve outcomes at&#x000a0;1 week; however, their study was small. The same group also reported a similar lack of effect when methocarbamol was added to oxycodone-acetaminophen, cyclobenzaprine, corticosteroids, and diazepam.<xref ref-type="bibr" rid="article-108904.r38">[38]</xref></p>
        <p>However, a retrospective cohort study published in 2024 examined injury risks linked to combining SMRs with commonly prescribed opioids in a US Medicaid population.&#x000a0;The study results&#x000a0;highlighted variations in injury rates based on specific SMR-opioid combinations and the order of initiation. Specifically focusing on methocarbamol, it demonstrated consistently lower injury rates compared to other SMRs like carisoprodol and tizanidine when used alongside oxycodone or tramadol. These results offer crucial insights into optimizing pain management strategies and underscore the necessity for further research to validate these findings and guide evidence-based clinical practice.<xref ref-type="bibr" rid="article-108904.r39">[39]</xref></p>
        <p>Clinicians should be vigilant while prescribing methocarbamol to older patients, those at risk of polypharmacy. Clinicians should keep in mind that there is no high-quality evidence to suggest methocarbamol is more effective than NSAIDs for acute musculoskeletal pain. Nurses and pharmacists should verify that methocarbamol is used only in select patients as part of multi-modal treatment with close monitoring of efficacy, adverse effects, and polypharmacy. Additionally, extensive randomized controlled trials are warranted to guide the clinical decision-making for a drug that appears to be a popular clinical tool for prescribers without solid evidence. Interprofessional collaborative work and&#x000a0;open&#x000a0;communication between physicians, nurse practitioners, physician assistants, nurses, and pharmacists could enhance patient outcomes related to methocarbamol.</p>
      </sec>
      <sec id="article-108904.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=108904&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=108904">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/108904/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=108904">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-108904.s11">
        <title>References</title>
        <ref id="article-108904.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <chapter-title>Methocarbamol</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">31643609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Tulder</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Touray</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Furlan</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Solway</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bouter</surname>
                <given-names>LM</given-names>
              </name>
              <collab>Cochrane Back Review Group</collab>
            </person-group>
            <article-title>Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the cochrane collaboration.</article-title>
            <source>Spine (Phila Pa 1976)</source>
            <year>2003</year>
            <month>Sep</month>
            <day>01</day>
            <volume>28</volume>
            <issue>17</issue>
            <fpage>1978</fpage>
            <page-range>1978-92</page-range>
            <pub-id pub-id-type="pmid">12973146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>See</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ginzburg</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Skeletal muscle relaxants.</article-title>
            <source>Pharmacotherapy</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>207</fpage>
            <page-range>207-13</page-range>
            <pub-id pub-id-type="pmid">18225966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'DOHERTY</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>SHIELDS</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Methocarbamol; new agent in treatment of neurological and neuromuscular diseases.</article-title>
            <source>J Am Med Assoc</source>
            <year>1958</year>
            <month>May</month>
            <day>10</day>
            <volume>167</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-3</page-range>
            <pub-id pub-id-type="pmid">13538683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>FORSYTH</surname>
                <given-names>HF</given-names>
              </name>
            </person-group>
            <article-title>Methocarbamol (robaxin) in orthopedic conditions; preliminary report of one hundred cases.</article-title>
            <source>J Am Med Assoc</source>
            <year>1958</year>
            <month>May</month>
            <day>10</day>
            <volume>167</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-8</page-range>
            <pub-id pub-id-type="pmid">13538684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>See</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ginzburg</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Choosing a skeletal muscle relaxant.</article-title>
            <source>Am Fam Physician</source>
            <year>2008</year>
            <month>Aug</month>
            <day>01</day>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>365</fpage>
            <page-range>365-70</page-range>
            <pub-id pub-id-type="pmid">18711953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qaseem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wilt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Forciea</surname>
                <given-names>MA</given-names>
              </name>
              <collab>Clinical Guidelines Committee of the American College of Physicians</collab>
              <name>
                <surname>Denberg</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Fitterman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Vijan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians.</article-title>
            <source>Ann Intern Med</source>
            <year>2017</year>
            <month>Apr</month>
            <day>04</day>
            <volume>166</volume>
            <issue>7</issue>
            <fpage>514</fpage>
            <page-range>514-530</page-range>
            <pub-id pub-id-type="pmid">28192789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richards</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Buchbinder</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The efficacy and safety of muscle relaxants in inflammatory arthritis: a Cochrane systematic review.</article-title>
            <source>J Rheumatol Suppl</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>90</volume>
            <fpage>34</fpage>
            <page-range>34-9</page-range>
            <pub-id pub-id-type="pmid">22942327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beebe</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Barkin</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Barkin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions.</article-title>
            <source>Am J Ther</source>
            <year>2005</year>
            <season>Mar-Apr</season>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>151</fpage>
            <page-range>151-71</page-range>
            <pub-id pub-id-type="pmid">15767833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patanwala</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Aljuhani</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Erstad</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Methocarbamol use is associated with decreased hospital length of stay in trauma patients with closed rib fractures.</article-title>
            <source>Am J Surg</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>214</volume>
            <issue>4</issue>
            <fpage>738</fpage>
            <page-range>738-742</page-range>
            <pub-id pub-id-type="pmid">28088301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Looke</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Kluth</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Effect of preoperative intravenous methocarbamol and intravenous acetaminophen on opioid use after primary total hip and knee replacement.</article-title>
            <source>Orthopedics</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2 Suppl</issue>
            <fpage>25</fpage>
            <page-range>25-32</page-range>
            <pub-id pub-id-type="pmid">23379573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abd-Elsalam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arafa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elkadeem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elfert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Elkhalawany</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Badawi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients.</article-title>
            <source>Eur J Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>499</fpage>
            <page-range>499-502</page-range>
            <pub-id pub-id-type="pmid">30444744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>UTTERBACK</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>TENNEY</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>METHOCARBAMOL IN THE THERAPY OF TETANUS.</article-title>
            <source>Arch Neurol</source>
            <year>1963</year>
            <month>Nov</month>
            <volume>9</volume>
            <fpage>555</fpage>
            <page-range>555-60</page-range>
            <pub-id pub-id-type="pmid">14057687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Escobar Gil</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McGeorge</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>A Case of Tizanidine Withdrawal and Road to Recovery.</article-title>
            <source>Cureus</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>e53444</fpage>
            <pub-id pub-id-type="pmid">38435197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>TRUITT</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>PATTERSON</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Comparative hemolytic activity of mephenesin, guaiacol glycerol ether and methocarbamol in vitro and in vivo.</article-title>
            <source>Proc Soc Exp Biol Med</source>
            <year>1957</year>
            <month>Jul</month>
            <volume>95</volume>
            <issue>3</issue>
            <fpage>422</fpage>
            <page-range>422-4</page-range>
            <pub-id pub-id-type="pmid">13453457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elenbaas</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Centrally acting oral skeletal muscle relaxants.</article-title>
            <source>Am J Hosp Pharm</source>
            <year>1980</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>1313</fpage>
            <page-range>1313-23</page-range>
            <pub-id pub-id-type="pmid">6999895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Comstock</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Manning</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Melikian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1990</year>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-4</page-range>
            <pub-id pub-id-type="pmid">2253675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dent</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Ervin</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Relief of acute musculoskeletal symptoms with intravenous methocarbamol (robaxin injectable): a placebo-controlled study.</article-title>
            <source>Curr Ther Res Clin Exp</source>
            <year>1976</year>
            <month>Nov</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>661</fpage>
            <page-range>661-5</page-range>
            <pub-id pub-id-type="pmid">825351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LEVENTEN</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>VACCARINO</surname>
                <given-names>FP</given-names>
              </name>
            </person-group>
            <article-title>Intravenous methocarbamol in 100 orthopedic patients.</article-title>
            <source>Curr Ther Res Clin Exp</source>
            <year>1960</year>
            <month>Oct</month>
            <volume>2</volume>
            <fpage>497</fpage>
            <page-range>497-500</page-range>
            <pub-id pub-id-type="pmid">13761355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hall</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Teratogens associated with congenital contractures in humans and in animals.</article-title>
            <source>Teratology</source>
            <year>1982</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>173</fpage>
            <page-range>173-91</page-range>
            <pub-id pub-id-type="pmid">7101197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spence</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Risk of injury associated with skeletal muscle relaxant use in older adults.</article-title>
            <source>Ann Pharmacother</source>
            <year>2013</year>
            <season>Jul-Aug</season>
            <volume>47</volume>
            <issue>7-8</issue>
            <fpage>993</fpage>
            <page-range>993-8</page-range>
            <pub-id pub-id-type="pmid">23821610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viswanathan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Urine bag as a modern day matula.</article-title>
            <source>ISRN Nephrol</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>215690</fpage>
            <pub-id pub-id-type="pmid">24959539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sannerud</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ator</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Methocarbamol: evaluation of reinforcing and discriminative stimulus effects.</article-title>
            <source>Behav Pharmacol</source>
            <year>1991</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-150</page-range>
            <pub-id pub-id-type="pmid">11224058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gahr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freudenmann</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Eller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;nfeldt-Lecuona</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Abuse liability of centrally acting non-opioid analgesics and muscle relaxants--a brief update based on a comparison of pharmacovigilance data and evidence from the literature.</article-title>
            <source>Int J Neuropsychopharmacol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>957</fpage>
            <page-range>957-9</page-range>
            <pub-id pub-id-type="pmid">24552880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Preston</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guarino</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1992</year>
            <month>Aug</month>
            <volume>262</volume>
            <issue>2</issue>
            <fpage>707</fpage>
            <page-range>707-20</page-range>
            <pub-id pub-id-type="pmid">1501118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dawwas</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Hennessy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brensinger</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Acton</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Bilker</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dublin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Manis</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Miano</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Oslin</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Pham Nguyen</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Soprano</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wiebe</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Signals of Muscle Relaxant Drug Interactions Associated with Unintentional Traumatic Injury: A Population-Based Screening Study.</article-title>
            <source>CNS Drugs</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>389</fpage>
            <page-range>389-400</page-range>
            <pub-id pub-id-type="pmid">35249204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tayar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jabbour</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saggi</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Apr</month>
            <day>18</day>
            <volume>346</volume>
            <issue>16</issue>
            <fpage>1253</fpage>
            <page-range>1253-4</page-range>
            <pub-id pub-id-type="pmid">11961161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Podrizki</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Methocarbamol and myasthenia gravis.</article-title>
            <source>JAMA</source>
            <year>1968</year>
            <month>Sep</month>
            <day>23</day>
            <volume>205</volume>
            <issue>13</issue>
            <fpage>938</fpage>
            <pub-id pub-id-type="pmid">5695627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corcuff</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Chardon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>El Hajji Ridah</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brossaud</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations.</article-title>
            <source>Endocr Connect</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>R87</fpage>
            <page-range>R87-R98</page-range>
            <pub-id pub-id-type="pmid">28566493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lebby</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Dugger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lipscomb</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Leikin</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Skeletal muscle relaxant ingestion.</article-title>
            <source>Vet Hum Toxicol</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-5</page-range>
            <pub-id pub-id-type="pmid">2327059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <article-title>2023 ACMT Annual Scientific Meeting Abstracts - San Diego, CA.</article-title>
            <source>J Med Toxicol</source>
            <year>2023</year>
            <month>Mar</month>
            <day>23</day>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>63</fpage>
            <page-range>63-168</page-range>
            <pub-id pub-id-type="pmid">36952114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dillon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paulose-Ram</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Skeletal muscle relaxant use in the United States: data from the Third National Health and Nutrition Examination Survey (NHANES III).</article-title>
            <source>Spine (Phila Pa 1976)</source>
            <year>2004</year>
            <month>Apr</month>
            <day>15</day>
            <volume>29</volume>
            <issue>8</issue>
            <fpage>892</fpage>
            <page-range>892-6</page-range>
            <pub-id pub-id-type="pmid">15082991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <collab>GBD 2016 Disease and Injury Incidence and Prevalence Collaborators</collab>
            <article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Sep</month>
            <day>16</day>
            <volume>390</volume>
            <issue>10100</issue>
            <fpage>1211</fpage>
            <page-range>1211-1259</page-range>
            <pub-id pub-id-type="pmid">28919117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartvigsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hancock</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kongsted</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Louw</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Genevay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karppinen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pransky</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sieper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smeets</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Underwood</surname>
                <given-names>M</given-names>
              </name>
              <collab>Lancet Low Back Pain Series Working Group</collab>
            </person-group>
            <article-title>What low back pain is and why we need to pay attention.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Jun</month>
            <day>09</day>
            <volume>391</volume>
            <issue>10137</issue>
            <fpage>2356</fpage>
            <page-range>2356-2367</page-range>
            <pub-id pub-id-type="pmid">29573870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foster</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Anema</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Cherkin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Fritz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Koes</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Peul</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>CG</given-names>
              </name>
              <collab>Lancet Low Back Pain Series Working Group</collab>
            </person-group>
            <article-title>Prevention and treatment of low back pain: evidence, challenges, and promising directions.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Jun</month>
            <day>09</day>
            <volume>391</volume>
            <issue>10137</issue>
            <fpage>2368</fpage>
            <page-range>2368-2383</page-range>
            <pub-id pub-id-type="pmid">29573872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Helfand</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>140</fpage>
            <page-range>140-75</page-range>
            <pub-id pub-id-type="pmid">15276195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedman</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Cisewski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Irizarry</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Davitt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Solorzano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nassery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pearlman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain.</article-title>
            <source>Ann Emerg Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>348</fpage>
            <page-range>348-356.e5</page-range>
            <pub-id pub-id-type="pmid">29089169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-108904.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hennessy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brensinger</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Miano</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bilker</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Dublin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Comparative Risk of Injury with Concurrent Use of Opioids and Skeletal Muscle Relaxants.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2024</year>
            <month>Jul</month>
            <volume>116</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-127</page-range>
            <pub-id pub-id-type="pmid">38482733</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
